交易 Accendra Health Inc - ACH 差價合約
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; various programs to provide logistics and marketing solutions to its suppliers; and contract logistics services to the pharmaceutical, biotechnology, and medical device industries offering a range of supply chain logistics services to manufacturers. In addition, it offers business services comprising order-to-cash, re-labeling, customer service, and returns management; and warehousing and transportation services consisting of storage, controlled-substance handling, cold-chain, emergency and export delivery, inventory management, and pick and pack services. The Global Products segment manufactures and sources medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. Its products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. The company provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians'' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Mechanicsville, Virginia.最新股票文章

收息股:股息率分布、選股風險框架與高息ETF配置分析
2026年港股收息股與高息ETF的股息率結構、派息可持續性風險、估值環境及行業分散配置邏輯,涵蓋銀行股、REITs、公用事業及能源板塊的風險收益特徵分析
08:35, 27 3月 2026

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026

